FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023893927> ?p ?o ?g. }

• W2023893927 endingPage "146" @default.
• W2023893927 startingPage "145" @default.
• W2023893927 abstract "The high mortality rates observed among pregnant women during the 1957 through 1958 influenza pandemic prompted the US Surgeon General to issue a report in 1960 that recommended routine seasonal influenza vaccination for pregnant women.1Burney L.E. Influenza immunization: statement.Public Health Rep. 1960; 75: 944Crossref PubMed Google Scholar During the past half century, recommendations in the United States have evolved, with influenza vaccination recommended for all pregnant women regardless of trimester beginning in 2004. Despite these recommendations, influenza vaccination rates among pregnant women were generally low (<15%) until the 2009 H1N1 influenza A pandemic when vaccination rates increased to about 50%.2Centers for Disease Control and PreventionInfluenza vaccination coverage among pregnant women–United States, 2010–11 influenza season.MMWR Morb Mortal Wkly Rep. 2011; 60: 1078-1082PubMed Google Scholar Although these higher vaccination rates have been sustained,2Centers for Disease Control and PreventionInfluenza vaccination coverage among pregnant women–United States, 2010–11 influenza season.MMWR Morb Mortal Wkly Rep. 2011; 60: 1078-1082PubMed Google Scholar we are still a long way from the goal of ensuring that all pregnant women are vaccinated against influenza. Part of the challenge with achieving this goal has been lingering concerns about safety of vaccination during pregnancy.2Centers for Disease Control and PreventionInfluenza vaccination coverage among pregnant women–United States, 2010–11 influenza season.MMWR Morb Mortal Wkly Rep. 2011; 60: 1078-1082PubMed Google ScholarSee related article, page 177 See related article, page 177 Pregnant women are typically excluded from clinical trials evaluating vaccine safety and effectiveness. Therefore, most information about vaccination during pregnancy comes from observational studies conducted following US Food and Drug administration (FDA) approval of vaccines. In the case of the seasonal influenza vaccine, we have accumulated many decades of experience vaccinating pregnant women without any major concerns about safety. A review of the literature published in 2009 did not identify any studies that documented an increased risk of adverse maternal or fetal effects with maternal influenza vaccination,3Tamma P.D. Ault K.A. Del Rio C. Steinhoff M.C. Halsey N.A. Omer S.B. Safety of influenza vaccination during pregnancy.Am J Obstet Gynecol. 2009; 201: 547-552Abstract Full Text Full Text PDF PubMed Scopus (228) Google Scholar and subsequent reviews of safety data during and following the 2009 H1N1 pandemic have been reassuring.4Moro P.L. Broder K. Zheteyeva Y. et al.Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System.Am J Obstet Gynecol. 2011; 205: 473.e1-473.e9Abstract Full Text Full Text PDF Scopus (87) Google Scholar, 5Pasternak B. Svanstrom H. Molgaard-Nielsen D. et al.Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark.BMJ. 2012; 344: e2794Crossref PubMed Scopus (101) Google Scholar The influenza vaccines licensed and used in the United States, however, do not contain adjuvants. Much less is known about the safety of adjuvants in pregnancy. Adjuvants are substances added to vaccines to boost the immune response and potentially provide longer-lasting and broader protection against antigenically drifted viruses.6Herberts C. Melgert B. Van Der Laan J.W. Faas M. New adjuvanted vaccines in pregnancy: what is known about their safety?.Expert Rev Vaccines. 2010; 9: 1411-1422Crossref PubMed Scopus (14) Google Scholar During a future pandemic, adjuvants could allow for use of lower doses of antigen at a time when the urgent demand for vaccine might outstrip production capacity. In addition, stockpiled prepandemic vaccines, produced against previously circulating highly pathogenic avian influenza H5N1 viruses, will likely require addition of an adjuvant to promote adequate immune response to a newly circulating H5N1 pandemic strain that has drifted antigenically since the vaccine was prepared. However, there are some theoretical concerns about the use of adjuvants in pregnancy.6Herberts C. Melgert B. Van Der Laan J.W. Faas M. New adjuvanted vaccines in pregnancy: what is known about their safety?.Expert Rev Vaccines. 2010; 9: 1411-1422Crossref PubMed Scopus (14) Google Scholar During pregnancy there are alterations of the immune system that occur to accommodate fetal and placental growth without triggering rejection of paternally derived antigens. How adjuvanted vaccines that elicit a robust immune response might affect pregnancy is unknown. Introduced in the 1920s, aluminum salts are the most common adjuvants and are used in a variety of vaccines including hepatitis A, hepatitis B, human papilloma virus, diphtheria, tetanus, pertussis, polio, and pneumococcal. Available data on the use of aluminum-based adjuvants during pregnancy are reassuring. Worldwide, many pregnant women have received tetanus toxoid vaccines containing an aluminum adjuvant with no increased risk of adverse pregnancy outcomes.6Herberts C. Melgert B. Van Der Laan J.W. Faas M. New adjuvanted vaccines in pregnancy: what is known about their safety?.Expert Rev Vaccines. 2010; 9: 1411-1422Crossref PubMed Scopus (14) Google Scholar Newer adjuvants have been developed more recently and include the oil-in-water emulsions such as AS03 and MF59. Although the safety of these newer adjuvanted vaccines in pregnancy has not been well studied in clinical trials, the 2009 H1N1 influenza pandemic offered a rare opportunity to evaluate adjuvanted vaccines in pregnancy because many European countries used adjuvanted 2009 H1N1 vaccines to vaccinate large numbers of pregnant women. Several studies assessed the safety of AS03-adjuvanted 2009 H1N1 vaccine in pregnant women. A relatively small prospective observational study of 267 women from the United Kingdom who were vaccinated with an AS03-adjuvanted 2009 H1N1 vaccine found no increased risk of adverse pregnancy outcomes including congenital anomalies.7Tavares F. Nazareth I. Monegal J.S. Kolte I. Verstraeten T. Bauchau V. Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study.Vaccine. 2011; 29: 6358-6365Crossref PubMed Scopus (64) Google Scholar A larger nationwide registry study from Denmark of >7000 pregnant women vaccinated with AS03-adjuvanted 2009 H1N1 vaccine was similarly reassuring with no increased risk of spontaneous abortion or fetal death.5Pasternak B. Svanstrom H. Molgaard-Nielsen D. et al.Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark.BMJ. 2012; 344: e2794Crossref PubMed Scopus (101) Google Scholar Several small studies have assessed the safety of MF59-adjuvanted 2009 H1N1 influenza vaccines8Parretta E. Ianniello B. Ferrazin F. Rossi F. Capuano A. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination.Vaccine. 2011; 29: 3708-3713Crossref PubMed Scopus (33) Google Scholar, 9Tsai T. Kyaw M.H. Novicki D. Nacci P. Rai S. Clemens R. Exposure to MF59-adjuvanted influenza vaccines during pregnancy–a retrospective analysis.Vaccine. 2010; 28: 1877-1880Crossref PubMed Scopus (47) Google Scholar, 10Zuccotti G. Pogliani L. Pariani E. Amendola A. Zanetti A. Transplacental antibody transfer following maternal immunization with a pandemic 2009 influenza A(H1N1) MF59-adjuvanted vaccine.JAMA. 2010; 304: 2360-2361Crossref PubMed Scopus (54) Google Scholar; collectively, these studies report use of MF59-adjuvanted vaccine among a total of <150 pregnant women. In this current issue of the American Journal of Obstetrics and Gynecology11Heikkinen T. Young J. van Beek E. et al.Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study.Am J Obstet Gynecol. 2012; 207: 177.e1-177.e8Abstract Full Text Full Text PDF Scopus (87) Google Scholar is an observational study of 2295 pregnant women who received MF59-adjuvanted 2009 H1N1 influenza vaccine and a comparison group of >2213 unvaccinated pregnant women. This study found no differences in rates of adverse pregnancy or birth outcomes between vaccinated and unvaccinated women. This study, representing the largest and most complete information on MF59 adjuvant use in pregnancy to date, provides reassuring data about its safety during pregnancy. However, as noted by the authors, the study had several limitations. These include the small number of first-trimester exposures, limited power to assess relatively rare outcomes (eg, individual birth defects), and a focus on outcomes that are present at or shortly after birth. Additional studies are needed to address these critical knowledge gaps. The 2009 H1N1 pandemic may not be the last influenza pandemic in our lifetimes. Circulation in many countries of highly pathogenic avian influenza A (H5N1) virus among birds with occasional transmission to human beings continues to raise concerns about a future pandemic. In addition, we are reminded of the risk of emergence of novel reassortant viruses by the recent reports of 13 persons in 6 US states infected with a novel reassortant influenza A (H3N2) variant (H3N2v) virus, which contains genes from human, swine, and avian influenza viruses, and the M gene from the 2009 H1N1 virus.12Centers for Disease Control and PreventionFirst H3N2 variant virus infection reported for 2012.http://www.cdc.gov/flu/spotlights/h3n2v-variant-utah.htmGoogle Scholar More research is needed on the safety of adjuvanted vaccines in pregnancy, particularly their use in the first trimester, to establish a more complete safety profile. Although determination of safety of a vaccine used during pregnancy is challenging and usually depends on data from studies initiated after FDA approval, studies performed during the 2009 H1N1 pandemic provide us with reassuring data regarding use of influenza vaccines during pregnancy, including adjuvanted vaccines. These data will be useful in weighing the potential risks and benefits of use of an adjuvanted influenza vaccine in the event of a future pandemic. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort studyAmerican Journal of Obstetrics & GynecologyVol. 207Issue 3PreviewThe 2009-2010 A/H1N1 pandemic provided a unique setting to study the safety of MF59-adjuvanted vaccination in pregnancy. Full-Text PDF" @default.
• W2023893927 created "2016-06-24" @default.
• W2023893927 creator A5023727621 @default.
• W2023893927 creator A5067842074 @default.
• W2023893927 date "2012-09-01" @default.
• W2023893927 modified "2023-09-24" @default.
• W2023893927 title "The safety of adjuvants in influenza vaccines during pregnancy: what do we know and why do we need them?" @default.
• W2023893927 cites W1964521095 @default.
• W2023893927 cites W2020148757 @default.
• W2023893927 cites W2022892378 @default.
• W2023893927 cites W2022972028 @default.
• W2023893927 cites W2059237935 @default.
• W2023893927 cites W2062068716 @default.
• W2023893927 cites W2085743609 @default.
• W2023893927 cites W2103476265 @default.
• W2023893927 cites W3020840468 @default.
• W2023893927 cites W4319308016 @default.
• W2023893927 cites W4376043781 @default.
• W2023893927 doi "https://doi.org/10.1016/j.ajog.2012.07.011" @default.
• W2023893927 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22939714" @default.
• W2023893927 hasPublicationYear "2012" @default.
• W2023893927 type Work @default.
• W2023893927 sameAs 2023893927 @default.
• W2023893927 citedByCount "9" @default.
• W2023893927 countsByYear W20238939272014 @default.
• W2023893927 countsByYear W20238939272018 @default.
• W2023893927 countsByYear W20238939272019 @default.
• W2023893927 countsByYear W20238939272021 @default.
• W2023893927 countsByYear W20238939272022 @default.
• W2023893927 countsByYear W20238939272023 @default.
• W2023893927 crossrefType "journal-article" @default.
• W2023893927 hasAuthorship W2023893927A5023727621 @default.
• W2023893927 hasAuthorship W2023893927A5067842074 @default.
• W2023893927 hasConcept C159047783 @default.
• W2023893927 hasConcept C177713679 @default.
• W2023893927 hasConcept C203014093 @default.
• W2023893927 hasConcept C22070199 @default.
• W2023893927 hasConcept C2778519782 @default.
• W2023893927 hasConcept C2779234561 @default.
• W2023893927 hasConcept C2780689484 @default.
• W2023893927 hasConcept C38652104 @default.
• W2023893927 hasConcept C41008148 @default.
• W2023893927 hasConcept C54355233 @default.
• W2023893927 hasConcept C71924100 @default.
• W2023893927 hasConcept C86803240 @default.
• W2023893927 hasConceptScore W2023893927C159047783 @default.
• W2023893927 hasConceptScore W2023893927C177713679 @default.
• W2023893927 hasConceptScore W2023893927C203014093 @default.
• W2023893927 hasConceptScore W2023893927C22070199 @default.
• W2023893927 hasConceptScore W2023893927C2778519782 @default.
• W2023893927 hasConceptScore W2023893927C2779234561 @default.
• W2023893927 hasConceptScore W2023893927C2780689484 @default.
• W2023893927 hasConceptScore W2023893927C38652104 @default.
• W2023893927 hasConceptScore W2023893927C41008148 @default.
• W2023893927 hasConceptScore W2023893927C54355233 @default.
• W2023893927 hasConceptScore W2023893927C71924100 @default.
• W2023893927 hasConceptScore W2023893927C86803240 @default.
• W2023893927 hasIssue "3" @default.
• W2023893927 hasLocation W20238939271 @default.
• W2023893927 hasLocation W20238939272 @default.
• W2023893927 hasOpenAccess W2023893927 @default.
• W2023893927 hasPrimaryLocation W20238939271 @default.
• W2023893927 hasRelatedWork W1563590313 @default.
• W2023893927 hasRelatedWork W2107367447 @default.
• W2023893927 hasRelatedWork W2167522942 @default.
• W2023893927 hasRelatedWork W2363400180 @default.
• W2023893927 hasRelatedWork W2767495920 @default.
• W2023893927 hasRelatedWork W2970762237 @default.
• W2023893927 hasRelatedWork W3197215834 @default.
• W2023893927 hasRelatedWork W4243063541 @default.
• W2023893927 hasRelatedWork W4252371801 @default.
• W2023893927 hasRelatedWork W4285236845 @default.
• W2023893927 hasVolume "207" @default.
• W2023893927 isParatext "false" @default.
• W2023893927 isRetracted "false" @default.
• W2023893927 magId "2023893927" @default.
• W2023893927 workType "article" @default.